Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 84.55%

Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin is 84.55% for the year ending December 31, 2023, a 1.12% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 83.61%, a -2.27% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 85.56%, a -2.70% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 87.93%, a 0.50% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 87.49%, a 1.03% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years